Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ISIS terrorists caught entering U.S. through southern border in last 36 hours
According to Judicial Watch, it has been confirmed by Homeland Security sources that four Islamic terrorists have been apprehended in the last 36 hours by federal authorities and the Texas Department of Public Safety in McAllen and Pharr. California Congressman Duncan Hunter, a former Marine Corp Major and member of the House Armed Services Committee, disclosed on national television that at least ten Islamic State of Iraq and Greater Syria (ISIS) fighters have been caught crossing the Mexican border in Texas.
A Texas National Guard soldier scans the Mexican side of the U.S.–Mexico border in Havana, Texas.
A Texas National Guard soldier scans the Mexican side of the U.S.–Mexico border in Havana, Texas.
Photo by John Moore/Getty Images
Hunter believes, “If you really want to protect Americans from ISIS, you secure the southern border.” He went on to point out that, "ISIS doesn’t have a navy, they don’t have an air force, they don’t have nuclear weapons. The only way that ISIS is going to harm Americans is by coming in through the southern border – which they already have.”
Rep. Jason Chaffetz, a Republican from Utah, said four alleged terror suspects were captured on Sept. 10 in Texas. In an interview with BuzzFeedNews on Wednesday, Chaffetz said the men flew from a Middle Eastern country to Mexico City, where they paid a smuggler to take them to and across the border. From there, the men ended up in a safe house for immigrants. They were en route to New York City, Chaffetz said, when they were captured.
Although Chaffetz would not reveal his source of the information, he said he confirmed it with government officials. “I had an informant tell me about it and then I questioned the Secretary of Homeland Security,” he said. “I have no doubt about its authenticity.”
CBS reported on Wednesday that the Department of Homeland Security released a statement that claims alleging Islamic State militants have been apprehended at the Mexican border are “categorically false.” The DHS insists they have no credible intelligence that suggests terrorist organizations are actively plotting to cross the southwest border. Homeland Security Secretary Jeh Johnson says that Islamic State militants are not entering the U.S. through the southern border. Johnson was responding to a claim made by Rep. Duncan Hunter, R-Calif., that at least 10 Islamic State operatives were detained trying to come in from Mexico.
Congressman Hunter, however, isn't buying that explanation. His spokesman told BuzzFeed News Wednesday that they have evidence from reliable sources about “foreign nationals” being captured along the border. Kasper said those foreign nationals may not technically be ISIS fighters, but do have suspected terror group affiliations. Kasper did not identify his sources but said that Hunter’s office remains convinced that the lawmaker was correct.
Our worst fears may already be realized because despite the recent surge of immigrants from Central America and other parts of the world at the southern border, the Obama administration has been unwilling to deploy the National Guard or other military assets to back up the Border Patrol. With the Border Patrol overwhelmed by a massive influx, illegal immigrants have been walking across the southern border into Texas from at least 75 different countries, and not just from Central America. Many of those apprehended in the Rio Grande area and elsewhere are released into the country after being initially detained by Border Patrol agents.
Is it plausible that ISIS is already in America after crossing the U.S.-Mexican border
Any books out there by investors who got rich on "hope"...? I didn't think so.
Well you have to call it like it is!!!
The Hope producers.
. . . . . SO JAZZY ..... :)
WHAT A JOKE, THEY'VE BEEN TRYING TO KNOCK IT DOWN ALL AM. PHLX MARKET MAKER KEEPS FLASHING ON THE BID.
COMPLETELY MANIPULATED, NO DOUBT.
ONLY PEOPLE TRADING THIS POS ARE HEDGIES AND SHORTERS
Seven straight weeks DOWN...down-trending moving averages showing their worth as they act as resistance. This sch!tty stock is a cancer in its own right.
PPHM is a wretched and rotten piece of garbage. Funny how the POS board goes hand in hand with that.
Personally, I believe the PR on Monday was that MUSHY PR, which did nothing for the Share Price. If last year was any indicator, then the PPS will continue to decrease to the ASM like it did last year.
October 2, 2013: $1.48
October 17, 2013 (ASM): $1.40
October 24, 2013: $.137
So far this year:
October 2, 2014: $1.32
October 16, 2014: My guess $1.18-$1.25...
Cloaked Protector working overtime tonight. Has an answer for everything. He must be so smart.
Yup. They have no skin in the game. They may have spent 10-25k on stock themselves. Options are meaningless. If that had any decent financial advice they would have been advised to load up on options and sell this pos. Look At the CEO of puma bio. He sold cougar bio and will do the same with puma bio. That's a CEO with a plan. That's how you make real money. Not nickel and diming on salaries. Idiots.
There riding the big salaries as long as they can. With a PIII in progress it can go another 2-3 if results are bad. If they are good then they have options. win/win for themselfs
BOD and management are completely incompetent. This should have been partnered or sold by now.
I think we get a few mushy PR's before the ASM and we go higher into meeting. but will get nothing out of ASM and we drift downward to RS after
If we wait any longer it will be $0.00
Who is CP anyway?
It's one big circle jerk over there with CP in the middle.
Management is perfect, you just wait what the pps will be.
I AGREE. STRAIGHT TO THE SLAUGHTERHOUSE. HE DOES KNOW EVERYTHING. DOESN'T HE? LOL. WHAT AMAZES ME IS HOW THESE IDIOTS ACTUALLY BELIEVE HIM AND THEY THINK HE IS HELPFUL. UNBELIEVABLE.
HE IS A PAID SCHILL ..........
AMAZING HOW HE THINKS HE HAS THE ANSWER TO EVERYTHING ....THE PIED PIPER OF PPHM LEADING PEOPLE TO THE SLAUGHTER .IMO
THE BULLSHIT HE SPEWS IS RELENTLESS !!!!!!!!!!!!
Who is paying Cloaked Protector to keep posting on the pos board?
I hope so. This is pathetic. What a bunch of amateurs running this pos
Do you think there is at least one spike left? I just want to get out now with a small loss instead of a large one.
DOWN SHE GOES.
WHEW! What a STENCH over there on the POS board...stock and posters...whew, that's some toxic sch!t! P.S. - DOO-DAH, DOO-DAH.
Hello all y'all!! FYI, BTW, FWIW NOVARTIS HAS DOUBLED DOWN ON CANCER BY SELLING THEIR NON CANCER DIVISIONS OFF FOR MEGA BILLIONS$$ like the vaccine/Hygienebiz for over $9 BILLION to Glaxo .... THINK CARTs and T CELL treatements for many types of cancer ... Through Sloan Kettering they do know of Bavituximab and down the road may be a "player" for either collaboration or buyout of PPHM ... JUZ SAYIN' ... Wink wink ..... Ciao & Shalom!!
PPHM could have a link with Ebola,and it's not a good one. If by chance the talking heads are lying to us and this turns into a pandemic,then the health care systems in the US and Europe will become overwhelmed. This could effectively hinder or kill our CT. I presently do not subscribe to this viewpoint,but think it is something to consider.
THANKS, JAKE. I KNOW WHO PETER K. IS AND I WAS ALSO TOLD HE WAS NOTBOB17, SO THAT WAS WHAT I WAS TRYING TO CLEAR UP.
RCJ
RCJ........
I THINK HE IS WRONG ON GOLFHO BEING PETER K ..
PETER K IS NOTBOB17 ..........
AND OUT OF RESPECT FOR PETER K I WON'T REVEAL WHO HE IS BUT A HINT WOULD BE A VERY FAMOUS GOLF ANNOUNCER AND TEACHER AND HE HAS BEEN IN PPHM AS LONG OR LONGER THAN ME..........
You know it's Admin not Mods that delete most post don't you? 95% of me deletions are admin not the mods. I can assure you Golfho's post (aka Peter K right) was an admin delete. PG
GOOD LORD ...IS THIS MAN A TOTAL IDIOT OR WHAT ???
DUBAI, United Arab Emirates (AP) — Vice President Joe Biden on Sunday called the crown prince of the United Arab Emirates to clarify that he did not mean to imply in his remarks last week that the Gulf ally was supporting al-Qaida fighters in Syria, the White House said.
Biden: I didn't mean to imply UAE aided al-Qaida Associated Press
UAE says Biden apologizes for any implication it supported militants Reuters
Biden apologizes to Turkey president in phone call Associated Press
Turkey's Erdogan attacks Biden claims it funded extremists AFP
Syria blasts coalition against Islamic State Associated Press
Biden spoke with Mohamed bin Zayed Al Nahyan, the crown prince of Abu Dhabi and a key Emirati leader, the White House said.
It was the second time in two days that Biden had to call a key partner in President Barack Obama's coalition to walk back comments he made on Thursday, when he said that U.S. allies — including Turkey, Saudi Arabia and the UAE — had funded and armed extremist groups linked to al-Qaida
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
UTSW Collaborators Found Phosphatidylserine (PS)-Targeting Antibody in Combination With an Anti-PD-1 or an Anti-CTLA-4 Immune Checkpoint Inhibitor Promotes a Robust, and Localized Anti-Tumor Response in Models of Melanoma and Breast Cancer; Statistically Significant Tumor Growth Suppression With Combination of PS-Targeting Antibody and Anti-PD-1 Versus Antibody Alone in Breast and Melanoma Models; Lead PS-Targeting Antibody Bavituximab in a Phase III Trial in Second-Line Non-Small Cell Lung Cancer and a First Immunotherapy Combination Trial With Ipilimumab (Yervoy(R)) in Advanced Melanoma
TUSTIN, CA -- (Marketwired) -- 10/06/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody. Data show that PS-targeting agents in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4, promote a robust and localized anti-tumor response in models of melanoma and breast cancer and decrease levels of myeloid derived suppressor cells (MDSC) in the tumor microenvironment. Newly generated data show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma. These data will be presented this morning at the Cancer Research Institutes' "Cancer Immunotherapy: Out of the Gate" conference being held at the Grand Hyatt Hotel in New York, New York.
"We are pleased to be presenting this exciting data to this immuno-oncology focused audience," said Jeff T. Hutchins, Ph.D. vice president, preclinical research at Peregrine Pharmaceuticals "These data are impressive and consistent in their findings across several tumor types and further build on the rationale for additional collaborative studies such as the ongoing investigator-sponsored Phase Ib trial of bavituximab in combination with ipilimumab (Yervoy®) in advanced melanoma."
The poster titled: "Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of immune checkpoint inhibitors by affecting myeloid-derived suppressor cell (MDSC) and lymphocyte populations in the tumor microenvironment" will be presented by Rolf Brekken, Ph.D., Effie Marie Cain Research Scholar in Angiogenesis Research and an Associate Professor, in the Departments of Surgery and Pharmacology at the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center in Dallas, Texas. Data from these studies show that the PS-targeting antibody ch1N11, the preclinical equivalent to bavituximab, significantly enhances tumor growth inhibition of anti-CTLA-4 or anti-PD-1 in the B16 and K1735 melanoma models and the efficacy of anti-PD-1 in the EMT-6 breast tumor model. New data show that the combination of ch1N11 and an anti-PD-1 antibody produce a statistically significant difference (p=0.018) in tumor growth suppression over anti-PD-1 alone in the B16 melanoma model. In addition, PS blockade with ch1N11 combined with either anti-CTLA-4 or anti-PD-1 resulted in greater T cell infiltration into B16 and K1735 tumors than tumors treated with either antibody alone. Consistent with these results, ch1N11 combined with anti-PD-1 showed an enhanced percentage of T cells producing the cytokines IL-2 and IFNg, factors associated with immune activation, when compared with T cells from tumors being treated with anti-PD-1 alone. In summary, the targeting and blocking of PS with ch1N11 significantly improved the anti-tumor efficacy of immune checkpoint blockade in robust models of melanoma and breast cancer in immunocompetent animals.
The link to the poster can be found from the front page of the company's website at: www.peregrineinc.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from potential human clinical studies involving combinations of PS-targeting agents with immune checkpoint inhibitors such as anti-PD-1 or anti-CTLA-4 may not correlate with the data from the preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Yervoy is a registered trademark of Bristol-Meyers Squibb.
Contact:
Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
JAKE. WE ALL KNOW IHUBS OWNERS HISTORY
IT JUST GOES TO SHOW HOW FUKKED UP POS BOARD REALLY IS..
ONE OF THE MOST RESPECTED POSTERS(GOLFHO) FOR A LONG LONG TIME POSTS AND EVERYONE SAYS WHAT A GREAT POST IT IS AND MODS DELETE IT ...THAT IS ONE GARBAGE BOARD OVER THERE ....LEMMY , I DON'T KNOW WHY YOU EVEN WASTE YOUR TIME WITH THEM.........
The idiots are enjoying themselves on the POS board.
Denial ain't a river in Egypt. And, there are less idiots in Egypt than on the POS board.
P-P-H-M sing dis song, DOO-DAH, DOO-DAH....
I see JAKE & you are finally coming around.
Bunch of f-ups and slime associated with the POS and POS board.
RAH RAH. PPS DOESN'T MATTER RIGHT??
You and me both. My response to Jeff was deleted but not his condescending post. I am out of faith in this, but will wait to sell. Surely this has one more pump left in it. Those thinking this will ever return $50-$100+ are delusional.
GWEN .......
YOUR PAL JEFF4IAM4 HAS HIS POM-POMS GOING FAST .. BUT HE HASN'T BEEN AROUND LONG ENOUGH TO SEE WHAT WE HAVE IN THE LAST 20 YEARS .....IT'S STILL A MIS-MANAGED COMPANY BY A PISS-POOR BOD ..I AM LOSING MORE AND MORE FAITH THAT WE WILL EVER SUCCEED BY THE MINUTE WITH THESE GUYS ......JAKE
MAYBE ANOTHER REVERSE SPLIT SINCE THE LAST TWO WORKED SO WELL.......
Imbeciles now claiming "manipulation" of POS. Typical cry of the pumping scoundrels.
Of course NOTHING at PPHM is what it's cracked up to be. It's a g.d. piece of sh*t. That's why it is a penny stock with a fishy BOD and a horrible reputation.
YIPPEE. CAN'T WAIT
GREAT NEWS!!! THANKS!
BIGGIE.....
EPCJMC SAID IT .......
I HAVE SOME NEWS FOR EVERYONE ...I AM SIERRA AND PPHM WILL OPEN UP AT 15.00 A SHARE ON MONDAY ....
Which moron over there said that?
Maybe I'm just getting beaten down by the incessant erosion, but I'm starting to think that Bavi isn't what it is cracked up to be. We should be seeing an increasing pps at this point in Phase III trials.
Now we gotta RETARD who is claiming he/she/it has special, close-hold information. Of course, he/she/it cannot say. Oh, no, we've never seen THAT before. What a idiot F-tard.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |